Take part in CCSN’s important survey on Xgeva!

The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of denosumab (Xgeva) for the prevention of skeletal-related events due to bone metastases from solid tumours. The information gathered from this survey will be used in order to prepare a patient evidence submission to

Canadians are paying the price for drug shortages, according to Canada’s hospital pharmacists, community pharmacists and physicians

OTTAWA, January 14, 2013 – According to the results of a new survey completed by over 1,070 members of the Canadian Pharmacists Association, Canadian Medical Association, and Canadian Society of Hospital Pharmacists in October 2012, drug shortages clearly remain a problem for Canada’s health system.  The survey confirms that the health and well?being of patients is

ZYTIGA™* (abiraterone acetate) receives Health Canada approval for treatment for metastatic prostate cancer

First Oral Treatment for Metastatic Prostate Cancer That Inhibits Androgen Production at All Three Sources Toronto, ON, July 28, 2011– Janssen Inc. announced today that after a priority review, Health Canada has approved ZYTIGA™ (abiraterone acetate), an oral medication for the treatment of men with metastatic prostate cancer. ZYTIGA™ is indicated with prednisone for the

New Medication to Reduce Bone Complications Now Available in Ontario

Patients with advanced prostate cancer gain access to first-in-class treatment OTTAWA, April 25, 2012 /CNW/ – Canadian Cancer Survivor Network (CCSN) is today congratulating the Ontario government for providing access to XGEVA® (denosumab) for the prevention of debilitating bone complications, known as skeletal-related events (SREs), in men with advanced prostate cancer which has spread to the bone.